About CLS Investment Criteria Our Team Scientific Advisors Portfolio News Contact


Amaranth Medical Reports Positive Safety and Feasibility Findings for the FORTITUDE™ Bioresorbable Scaffold
October 28, 2013

KFx Medical Corporation Receives $29 Million Award and a Finding of Willful Infringement by Arthrex Inc. in Patent Infringement Case
October 9, 2013

Amaranth Medical Raises $20 Million in Series B to Support Development of the FORTITUDE™ Bioresorbable Scaffold
October 7, 2013

KFx Medical Corporation Announces License of Its Knotless Double Row Patents
August 15, 2013

EnteroMedics Submits PMA Application for FDA Approval of VBLOC Therapy in Obesity
June 25, 2013

Mirabilis Medica, Woman's Healthcare Company, Announces Initial Closing In Financing Of Up To $13 Million Led By GSR Ventures
June 17, 2013

Insiders, New Investors to Join $25M Series B Round for Amaranth Medical
June 13, 2013

KFx Medical Corporation announces allowance from United States Patent Office of two additional orthopedic surgical patents
May 22, 2013

Takeda to Acquire Inviragen, Inc. - Obtains Promising Vaccine Candidates Against Dengue and Hand, Foot and Mouth Disease, Advancing Takeda's Commitment to Vaccines and Global Health
May 7, 2013

Inviragen Advances DENVax into Second Stage of Ongoing Phase 2 Clinical Study
February 27, 2013

VABIOTECH Licenses Cell-Based Japanese Encephalitis Technology from Inviragen
January 3, 2013

Inviragen and the International Vaccine Institute Expand Partnership - Studies will Examine Dengue Impact in Asia and Latin America
November 8, 2012

EnteroMedics Announces EMPOWER Trial Hypertension Data Presented at the American Heart Association's 2012 Scientific Sessions
November 7, 2012

Health Fidelity and Intelligent Medical Objects (IMO) Sign Multi-Year Agreement to Leverage Clinical Expertise and Solutions
October 31, 2012

Health Fidelity Releases REVEAL Version 2.0
September 25, 2012

Integrated Document Solutions Selects Health Fidelity's REVEAL™ to Improve Hospital Systems Revenue Cycle Management
August 9, 2012

AXIOS™ Stent and Delivery System CE Mark Approval Expanded to Include Biliary Tract Drainage - Offers New Endoscopic Options for Treating the Gallbladder and Bile Duct
July 17, 2012

Great Lakes Pharmaceuticals, Inc. announced today the initiation of the clinical study of the first Company product, the antimicrobial lock solution, B-Lock™
July 12, 2012

Health Fidelity REVEAL v1.1 Extracts Unstructured Clinical Data
July 12, 2012

ZyDoc Selects Health Fidelity’s REVEAL™ NLP Platform to Accelerate Time to Value for its MediSapien Web Services
June 12, 2012

EnteroMedics Announces First Commercial Implants of the Maestro(R) Rechargeable System
June 5, 2012

EnteroMedics Added to Russell 3000(R) and Russell 2000(R) Indexes
June 5, 2012

Health Fidelity REVEAL Helps Drive Quality Improvement, Care Efficiency and Information Exchange
April 26, 2012

EnteroMedics Announces First Commercial Shipment of the Maestro(R) Rechargeable System to Australia
April 3, 2012

EnteroMedics Announces 2.5-Year Diabetes, Hypertension and Weight Loss Data From the Maestro(R) RC System DM2 ENABLE Study
April 3, 2012

March 12, 2012

BayScribe Selects Health Fidelity's NLP Platform
March 6, 2012

U.S. Study Says Eye Care Professionals Would Switch 36% Of Their Presbyopic Patients Using Eyeglasses To A New Easy-To-Fit Contact Lens Design For Presbyopia
Feburary 28, 2012

Program from Health Fidelity accelerates integration of clinical natural language processing (NLP), bolstering the HIT ecosystem
Feburary 20, 2012

Columbia Grants Health Fidelity Exclusive License to MedLEE NLP
January 11, 2012

EnteroMedics Announces Completion of Patient Enrollment and Device Implantation in the ReCharge Pivotal Trial for Obesity
December 28, 2011

EnteroMedics Receives First Approval for the Active Implantable Medical Device Components of the Maestro System From Australian Therapeutic Goods Administration (TGA)
December 13, 2011

Inviragen Presents Safety and Immune Response Data from a Phase 1 Study of its Two-Dose Dengue Vaccine, DENVax
December 7, 2011

EnteroMedics Announces Updated Data From VBLOC DM2 ENABLE Study and Caloric Intake Study Results to Be Presented at the 29th Annual Obesity Society Meeting
October 3, 2011

EnteroMedics Announces Presentation of Maestro(R) RC System Clinical Data at the XVI World Congress of the International Federation for the Surgery of Obesity and Metabolic Disorders
September 2, 2011

Inviragen and University of Texas Medical Branch Receive Funding for Development of a Novel Recombinant Chikungunya Virus Vaccine
August 15, 2011

San Diego's KFx Medical Corporation Files Patent Infringement Suit Against Arthrex
August 2, 2011

International Vaccine Institute and Inviragen Announce a Collaboration to Accelerate Development of a Dengue Vaccine
August 2, 2011

Minimally Invasive Devices, Inc. Awarded CE Mark for FloShield
July 20, 2011

Inviragen Initiates Phase 1 Study of Hand, Foot and Mouth Disease Vaccine in Singapore
June 15, 2011

EnteroMedics Announces Maestro® RC System Updated Weight Loss Data to Be Presented at the American Society for Metabolic and Bariatric Surgery Annual Meeting
June 14, 2011

EnteroMedics Announces First Implant in ReCharge Pivotal Trial for Obesity
May 18, 2011

Xlumena, Inc. Closes $7M Series B Venture Financing Round
April 28, 2011

EnteroMedics Receives CE Mark Certification for the Maestro RC System, Allowing Australian Regulatory Application to Move Forward
March 28, 2011

Inviragen and Duke-NUS Form Collaborative Vaccine Research and Development Program
January 26, 2011

EnteroMedics Announces Data From Australian Patient Cohort in EMPOWER Study and From Caloric Intake Study
November 8, 2010

Novel Recombinant Chikungunya Virus Vaccine Shown to be Safe and Effective in Multiple Animal Models
November 4, 2010

Inviragen Receives Two Therapeutic Discovery Project Grants for Vaccine Development
November 2, 2010

Inviragen Initiates DENVax Phase 1 Clinical Testing in Colombia
October 25, 2010

EnteroMedics Announces Updated Data from VBLOC-DM2, EMPOWER and VBLOC RF2 Studies
October 20, 2010

Inviragen and PharmaJet Receive $15.5 Million NIAID Contract to Develop a Needle-free Dengue Vaccine
October 12, 2010

EnteroMedics Completes $6.3 Million Convertible Preferred Stock Offering
September 30, 2010

EnteroMedics Achieves Major Milestones in Global Regulatory and Commercialization Strategy for the Maestro System
August 2, 2010

KFx Medical Corporation Announced Today It Has Received FDA 510k Clearance for Product(s) Used in a Wide Variety of Arthroscopic Tenodesis Knee Procedures Such as: ACL, PCL, and Patellofemoral Ligament (MPFL) Reconstruction
May 25, 2010

Inviragen’s Dengue Vaccine to Begin Clinical Testing
May 19, 2010

Inviragen Merger Profiled in Inc. Magazine
May 7, 2010

FDA Clears Xlumena’s NAVIX™ Access Device
April 28, 2010

EnteroMedics Extends Neuroblocking Technology Research and Development Collaboration
March 17, 2010

EnteroMedics Announces Regulatory Path Forward Following FDA Meeting
March 15, 2010

EnteroMedics Announces Regulatory Path Forward Following FDA Meeting
January 28, 2010

EnteroMedics Announces Weight Loss, Hypertension and Diabetes Data from EMPOWER and ENABLE Studies
Januray 14, 2010

EnteroMedics Announces Preliminary Results from Detailed Review of EMPOWER Study
November 12, 2009

Inviragen Merges with SingVax and Completes $15 million Series A Financing
October 6, 2009

KFx Medical Awarded Key Patent for Knotless Tissue Fixation and Double Row Rotator Cuff Surgery
September 9, 2009

Visioneering Technologies Raises $2.5M Series B
April 28, 2009

Visioneering Technologies Inc Raises $5 Million in Funding For New Presbyopia Solution
April 14, 2009

EnteroMedics Announces $15.89 Million Private Placement
February 20, 2009

EnteroMedics Announces Eighteen-Month Excess Weight Loss Results from its VBLOC-RF2 Feasibility Study
January 12, 2009

EnteroMedics Announces $20 Million Debt Financing
November 21, 2008

APT Pharmaceuticals Secures $32 Million in Series B Financing
September 30, 2008

EnteroMedics' Data from VBLOC-RF2 Feasibility Study and VBLOC-RC Study Presented Today at the American Society for Metabolic and Bariatric Surgery Meeting
June19, 2008

XLumena Spots $6M For Ultrasound Devices
June 4, 2008

Mirabilis Completes First Human Trial of Non-Invasive Treatment for Uterine Fibroids
APRIL 28, 2008

Astellas and CoMentis Sign Agreement to Collaborate on the Research, Development and Commercialization of Beta-Secretase Inhibitors
APRIL 25, 2008

EnteroMedics Announces Planned Expansion of EMPOWER Pivotal Study for Obesity to 300 Patients
February 26, 2008

KFx Medical Corporation Appoints Matt Meyer as its Vice President Marketing
February 20, 2008

EnteroMedics(TM) Announces Nine-Month Clinical Results on Its VBLOC-RF2 Feasibility Study for Obesity Therapy
January 8, 2008

EnteroMedics(TM) Announces Pivotal Clinical Study of its VBLOC(TM) Therapy for Obesity
January 7, 2008

CoMentis Announces Proof-of-Activity-Data from its Phase I Study of Disease-Modifying Alzheimer’s Disease Therapy
January 7, 2008

APT Pharmaceuticals Expands Management Team
NOVEMBER 19, 2007

EnteroMedics Announces Initial Public Offering
NOVEMBER 14, 2007

APT Pharmaceuticals Closes New $22 Million Funding Round
OCTOBER 4, 2007

JDRF Partners with CoMentis for Diabetic Macular Edema Clinical Trial
SEPTEMBER 20, 2007

Mirabilis Closes $10.5 Million Series A Extension to Commercialize Non-invasive Treatment of Uterine Fibroids
AUGUST 21, 2007

KFx Medical Corporation Closes $10 Million Series B Financing
AUGUST 9, 2007

JDRF Partners with CoMentis for Diabetic Macular Edema Clinical Trial
JUNE 18, 2007

CoMentis Announces Appointment of Martin Tolar, M.D., Ph.D., as Vice President
JUNE 6, 2007

APT Acquires Exclusive Worldwide Rights to Develop and Commercialize Inhalable Cyclosporine to Prevent Lung Transplant Rejection
JUNE 5, 2007

Enteromedics Files Registration Statement
for Proposed Initial Public Offering
MAY 25, 2007

CoMentis Initiates Phase II Clinical Trial for AMD Eye Drop Therapy
APRIL 10, 2007

Athenagen Announces Name Change to CoMentis
FEBRUARY 10, 2007

Athenagen’s Eye Drop Therapy for AMD is Safe and Well Tolerated in Phase I Study
JANUARY 31, 2007

Athenagen Initiates Phase II Clinical Trial in Alzheimer’s Disease
DECEMBER 13, 2006

Mirabilis Medica Names Mike Connolly CEO
OCTOBER 3, 2006

Athenagen Raises $50 Million in Series B Financing
SEPTEMBER 28, 2006

Amaranth Medical Closes $7.5 Million Series A Financing to Advance the Development of Bio-Absorbable Stents
SEPTEMBER 26, 2006

Mirabilis Raises $4 Million to Commercialize Non-Invasive Treatment of Uterine Fibroids
AUGUST 29, 2006

Athenagen Initiates Clinical Development of its Anti-angiogenic Eye Drop Therapy for AMD
AUGUST 21, 2006

Athenagen Completes Merger with Zapaq
AUGUST 14, 2006

KFx Medical Corporation Receives 510k Clearance for Knotless Tissue Fixation
AUGUST 10, 2006

Athenagen Announces Publication of Results from a Proof-of-Concept Trial of its Novel alpha-7 Nicontinic Receptor Agonist in Schizophrenia
JUNE 15, 2006

Athenagen Acquires Osprey Pharmaceutical Company - Adds Clinical-Stage Alzheimer's Drug Candidate to its Pipeline
APRIL 13, 2006

Aradigm and APT Pharmaceuticals Initiate Phase 2 Clinical Program of Novel Treatment for Asthma
MARCH 23, 2006

Athenagen Adds A. Barr Dolan to its Board of Directors
FEBRUARY 22, 2006

Previous News Stories >

  About CLS  


CHARTER LIFE SCIENCES (“CLS”) is a clinical stage life sciences venture capital investor. CLS makes initial portfolio company investments in life sciences companies that are seeking capital to obtain initial clinical proof-of-efficacy of their products (see Investment Criteria), and we continue to support our successful portfolio companies with follow on investments until they are acquired or go public.

Our team is led by four Managing Partners who have worked together to create and build life sciences companies for over twenty years. We take a team approach to all of our investments, and our team brings extensive scientific, clinical, regulatory, operational and finance experience to each of our portfolio companies.

We play an active role in helping entrepreneurs build successful companies. Our time, energy and passion is devoted to investing in early stage life sciences opportunities. As a result, your company will be compared only against other early stage opportunities. So, at CLS, your preclinical biotech or medical device company will not be compared against a PIPE investment in an undervalued Phase III company. Early stage is what we do, and all we do.

We understand that early stage companies do not have all the answers and do not have all the data. We understand that many basic questions need investment capital to answer, and we understand that development plans and milestones are subject to lots of uncertainty and change. We understand what it takes to build a management team from scratch, and we invest in companies with little or no existing management. In short, we understand what it is to be an early stage entrepreneur, because each of us has been one.

Please look carefully at our investment criteria and our team, and if we are the type of partner that you would like to work with, please contact us.